Properties (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Takeda_Pharmaceutical_Company
2019 |
| gptkbp:CEO |
gptkb:Christophe_Weber
|
| gptkbp:clinicalTrials |
ongoing
|
| gptkbp:employees |
over 23,000
|
| gptkbp:focus_area |
hematology
genetic diseases neuroscience immunology gastroenterology |
| gptkbp:founded |
1986
|
| gptkbp:founder |
gptkb:Jeffrey_M._Leiden
|
| gptkbp:headquarters |
gptkb:Lexington,_Massachusetts
|
| https://www.w3.org/2000/01/rdf-schema#label |
Shire Pharmaceuticals
|
| gptkbp:market |
$62 billion (2018)
|
| gptkbp:notableFeature |
gptkb:Fosrenol
Adderall Cerezyme Intuniv Vyvanse |
| gptkbp:operates_in |
over 100 countries
|
| gptkbp:partnerships |
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer Sanofi |
| gptkbp:products |
medical devices
clinical services market access solutions medications biopharmaceuticals therapeutics data management solutions therapeutic areas digital health solutions patient engagement tools patient support programs diagnostics oral medications topical treatments injectables value-based care solutions clinical research services real-world evidence solutions outcomes research solutions healthcare_analytics healthcare_solutions |
| gptkbp:researchAndDevelopment |
focus on rare diseases
|
| gptkbp:revenue |
$15.2 billion (2018)
|
| gptkbp:specializesIn |
rare diseases
|
| gptkbp:subsidiary |
gptkb:Shire_Pharmaceuticals_Ireland_Limited
gptkb:Shire_Human_Genetic_Therapies gptkb:Shire_Regenerative_Medicine gptkb:Shire_US_Inc. gptkb:Shire_Development_LLC |